Trial Profile

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Romilkimab (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Therapeutic Use
Acronyms ESTAIR
Sponsors Sanofi

Most Recent Events

18 Oct 2018 Results (n=325) published in the European Respiratory Journal
19 Sep 2018 Results assessing the efficacy and safety of SAR156597 prevalence and clinical significance of antinuclear antibody (ANA) in idiopathic pulmonary fibrosis (IPF) patients, presented at the 28th Annual Congress of the European Respiratory Society.
23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com